Abstract
A clinical decision report using:
Søfteland E, Meier JJ, Vangen B, Toorawa R, Maldonado-Lutomirsky M, Broedl UC. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial. Diabetes Care. 2016;40(2):201-209. https://doi.org/10.2337/dc16-1347
for a patient with uncontrolled type 2 diabetes on metformin and sitagliptin and hesitant to begin insulin therapy.
DOI
10.22237/crp/1622160600
Creative Commons License
This work is licensed under a Attribution 4.0 International (CC-BY 4.0) License
Recommended Citation
DARIAN MA. Starting triple oral hypoglycemic agent therapy in poorly controlled type 2 diabetes is a suitable therapeutic strategy to lower HbA1c when insulin therapy is not desired. Clin. Res. Prac. Jun 29 2021;7(1):eP2585. https://doi.org/10.22237/crp/1622160600
Included in
Behavioral Medicine Commons, Community Health Commons, Endocrinology, Diabetes, and Metabolism Commons
